肾小球疾病补体蛋白分析:激光显微切割与质谱的见解
本文综述了激光显微切割与质谱(LMD/MS)在肾小球疾病补体蛋白分析中的应用。该方法可深度评估补体蛋白、调节蛋白、补体途径及活性片段,并半定量补体负荷。不同肾小球疾病的补体蛋白谱存在重要差异,甚至在同一疾病不同抗原间也有变化。LMD/MS有助于个体化抗补体治疗。
要点
- LMD/MS可全面分析肾活检补体蛋白、调节蛋白及补体途径。
- 不同肾小球疾病及同一疾病不同抗原的补体谱存在差异。
- LMD/MS有助于指导个体化抗补体治疗。
核心结论
- LMD/MS是确定肾小球疾病补体蛋白、调节蛋白、补体途径及补体负荷的有价值工具。
研究设计与样本
- 综述,采用激光显微切割与质谱(LMD/MS)分析肾小球疾病补体蛋白谱。
主要发现
- 不同肾小球疾病的补体谱(包括补体途径)存在重要差异。
- 同一疾病不同抗原本间补体负荷和谱也有改变,如膜性肾病。
临床怎么用
- 在抗补体药物时代,LMD/MS可帮助准确确定每个肾活检的补体谱,实现个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Complement activation occurs in most glomerular diseases. Complement activation on the kidney biopsy is evidenced by deposition of C3c and C1q on the kidney biopsy. The kidney biopsy provides only limited information as other complement proteins and complement-regulating proteins are not typically studied. Furthermore, kidney biopsy does not distinguish between activated versus inactive complement proteins. Laser microdissection and mass spectrometry (LMD/MS) is a relatively new methodology that can provide an in-depth evaluation of the proteomic profile of complement proteins, complement regulating proteins, complement pathways, and can also determine whether active complement fragments are present in the kidney biopsy sample. A semiquantitative burden of complement can be determined. Furthermore, proteins of a disease can be analyzed using principal component analysis, volcano plots, and heatmaps. In this review, the complement proteomic profile of diseases representing the spectrum of glomerular diseases are shown. The proteomic complement profile of membranous nephropathy associated with various antigens, Ig-associated GN, such as proliferative GN with monoclonal Ig deposits and fibrillary GN, C3 glomerulopathy, and IgA nephropathy, are shown. The findings show important differences in the complement profile including pathways of complement in each disease, and even within the disease, such as altered complement burden and profile between different antigens associated with membranous nephropathy. In conclusion, LMD/MS is a valuable tool for determining the complement proteins, complement-regulating proteins, complement pathways, and determining the burden of complement in each individual case of glomerular disease. In the era of new anticomplement drugs, it will become essential to accurately determine the complement profile in each kidney biopsy for a personalized approach to treating the glomerular disease. LMD/MS is a methodology that can help provide such answers.
引用
- Sethi S. Complement Profiling in Glomerular Disease: Insights from Laser Microdissection and Mass Spectrometry. Clin J Am Soc Nephrol. 2025. PMID: 41159815. doi:10.2215/CJN.0000000943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。